<code id='C15C76BF77'></code><style id='C15C76BF77'></style>
    • <acronym id='C15C76BF77'></acronym>
      <center id='C15C76BF77'><center id='C15C76BF77'><tfoot id='C15C76BF77'></tfoot></center><abbr id='C15C76BF77'><dir id='C15C76BF77'><tfoot id='C15C76BF77'></tfoot><noframes id='C15C76BF77'>

    • <optgroup id='C15C76BF77'><strike id='C15C76BF77'><sup id='C15C76BF77'></sup></strike><code id='C15C76BF77'></code></optgroup>
        1. <b id='C15C76BF77'><label id='C15C76BF77'><select id='C15C76BF77'><dt id='C15C76BF77'><span id='C15C76BF77'></span></dt></select></label></b><u id='C15C76BF77'></u>
          <i id='C15C76BF77'><strike id='C15C76BF77'><tt id='C15C76BF77'><pre id='C15C76BF77'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:1566
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          PBMs are inflating the cost of generic drugs. They must be reined in
          PBMs are inflating the cost of generic drugs. They must be reined in

          AdobeThesearenotcomfortabledaysinWashingtonforpharmacybenefitmanagers,thehighlyconsolidatedgroupofin

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          How the first Native Hawaiian psychiatrist helped diversify medicine

          BenYoungblowingaconchshellonaround-the-worldcanoetripin2017.BenjaminB.YoungBenjaminYoungdidn’tsetout